Table 3.
Comparison of clinical profile between progressors and non‐progressors
| Progresssors | Non‐progressors | P‐values | |
|---|---|---|---|
| No. cases | 44 | 114 | |
| Age (years) | 57.3 ± 10.2 | 59.2 ± 9.1 | 0.549 |
| Duration of diabetes (years) | 5.3 ± 7.7 | 4.6 ± 6.7 | 0.621 |
| Men/women | 28/16 (63.65/36.4%) | 79/35 (69.3%/30.7%) | 0.492 |
| Body mass index (kg/mm2) | 24.0 ± 3.5 | 24.6 ± 4.0 | 0.354 |
| HbA1c (NGSP) (%) | 6.8 ± 0.7 | 6.9 ± 0.8 | 0.656 |
| IFCC (mmol/mol) | 50.8 ± 7.6 | 51.9 ± 8.7 | |
| Blood glucose (casual) | 8.2 ± 2.6 | 8.3 ± 2.5 | 0.891 |
| Systolic blood pressure (mmHg) | 131 ± 12 | 133 ± 12 | 0.489 |
| Total cholesterol (mmol/L) | 4.5 ± 0.5 | 4.6 ± 0.6 | 0.112 |
| LDL cholesterol (mmol/L) | 2.3 ± 0.4 | 2.4 ± 0.5 | 0.059 |
| Triglyceride (mmol/L) | 1.4 ± 0.8 | 1.5 ± 0.8 | 0.470 |
| Hypertension | 61.0% | 69.3% | 0.341 |
| Arteriosclerosis | 56.8% | 54.4% | 0.786 |
| Retinopathy | 43.2% | 43.9% | 0.937 |
| Nephropathy | 31.8% | 26.3% | 0.489 |
| Neuropathy | 25.0% | 26.3% | 0.480 |
| Stage (I/II/III/IV+V) | 79.5/20.5/0/0% | 85.1/13.2/1.0/0% | 0.252 |
Progressors showed decline of compound muscle action potentials (CMAP) in both median and tibial nerve while non‐progressors did not show decline of CMAP either median or tibial nerves. HbA1c, glycated hemoglobin; IFCC, International Federation of Clinical Chemistry; LDL, low‐density lipoprotein; NGSP, National Glycohemoglobin Standardization Program.